Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 157

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 1A
Chunk 157
---
 underlying such Senior Convertible Notes.

In such events or in the event of any other redemption event or event of default under the Oramed Note or the Senior Convertible Notes, we may not have enough available cash or be able to obtain financing at the time we are required to pay cash with respect to the Oramed Note or the Senior Convertible Notes. In addition, our ability to pay cash upon default of the Oramed Note or the Senior Convertible Notes may be limited by law, regulatory authority, or any agreements governing our future indebtedness.

We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. 

Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our commercialization efforts for ZTlido, GLOPERBA and ELYXYB, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. 

 67

As of September 30, 2024, our cash and cash equivalents were approximately $0.1 million and we had an accumulated deficit of approximately $556.6 million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: 

•the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; 

•the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; 

•the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; 

•the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; 

•the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; 

•the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; 

•the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; 

•our ability to maintain existing, and establish new, strategic collaborations, licensing